Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020

Ayumi President Hikaru Oouchi Ayumi Pharmaceutical, a rheumatic and orthopedic specialty pharma born last year, is set to in-license several biosimilars for rheumatoid arthritis (RA) treatments and leverage them to attain sales of 50 billion yen by 2020, President Hikaru...read more